![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka America Pharmaceutical, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 24, 2022